Document Detail


Prospective randomized trial of transthoracic versus low-energy transvenous internal cardioversion in persistent atrial fibrillation.
MedLine Citation:
PMID:  15529558     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Electrical cardioversion (CV) is used to restore sinus rhythm (SR) in patients with atrial fibrillation (AF). In this prospective randomized study, we compared two different methods of electrical CV, namely transthoracic (TT) and low-energy transvenous internal CV (ICV), in patients with persistent AF with respect to efficacy, safety and the magnitude of myocardial damage provoked by either method. METHODS AND RESULTS: Fifty-two patients with persistent AF were randomly assigned to either TT (n = 26) or ICV (n = 26). The baseline characteristics of the two treatment groups were similar. TT CV was performed under sedation with hand-held electrodes in the apex-anterior position and high-energy (100-360J) monophasic shocks. ICV was performed by a single catheter approach utilizing a special balloon-directed catheter with proximal and distal arrays of shock electrodes that were positioned in the right atrium and left pulmonary artery under fluoroscopy. Truncated, biphasic shocks of low energy (1-15 joules) were used. Cardiac troponin T (cTpnT), creatine kinase (CK) and CK-MB levels were assessed before and 24 hours after each procedure. SR was restored in 24/26 (92%) patients in the ICV and 22/26 (85%) patients in the TT CV groups (p > 0.05). The mean energy to achieve SR was significantly higher with the TT method (9.8 +/- 4.3 J vs. 246.4 +/- 73.6 J, p < 0.05). CV with either method caused no elevation in cTpnT levels. Total CK and CK-MB levels remained unchanged with ICV. On the other hand, TT CV resulted in a significant increase in total CK (51.8 +/- 30 vs. 156.5 +/- 255.3, p < 0.05) and a nonsignificant rise in CK-MB levels (14.7 +/- 7 vs. 17.3 +/- 1.1, p > 0.05). CONCLUSIONS: In this prospective randomized comparison, TT and ICV were found to be equally effective to restore SR in patients with persistent AF No evidence of myocardial damage was detected with either method.
Authors:
Ridvan Yalçin; Mehmet Güngör Kaya; Murat Ozdemir; Mustafa Cemri; Timur Timurkaynak; Bülent Boyaci; Atiye Cengel
Related Documents :
19341858 - Paroxysmal lone atrial fibrillation is associated with an abnormal atrial substrate: ch...
18680608 - Melasma and its association with different types of nevi in women: a case-control study.
14994848 - Rate versus rhythm control in atrial fibrillation.
16768058 - Impact of hispanic ethnicity on the likelihood of developing postoperative atrial fibri...
7657008 - Hyponatraemia and non-electrolyte solutions in labouring primigravida.
901698 - Determinants of anticoagulant control in patients receiving warfarin.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Acta cardiologica     Volume:  59     ISSN:  0001-5385     ISO Abbreviation:  Acta Cardiol     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-11-08     Completed Date:  2005-02-07     Revised Date:  2009-06-11    
Medline Journal Info:
Nlm Unique ID:  0370570     Medline TA:  Acta Cardiol     Country:  Belgium    
Other Details:
Languages:  eng     Pagination:  521-6     Citation Subset:  IM    
Affiliation:
Department of Cardiology, School of Medicine, Gazi University, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Atrial Fibrillation / blood,  therapy*
Chronic Disease
Electric Countershock / adverse effects,  methods*
Electrophysiologic Techniques, Cardiac
Female
Humans
Male
Middle Aged
Prospective Studies
Treatment Outcome
Troponin T / blood
Chemical
Reg. No./Substance:
0/Troponin T

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Plasma interleukin-6 levels are increased in coronary artery ectasia.
Next Document:  Haemoglobin level influences plasma brain natriuretic peptide concentration.